{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124542","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.474660+00:00","generated_at":"2026-05-30T02:20:26.272462+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Apogee Therapeutics Reports Q3 2024 Financial Results and Pipeline Progress","bullets":["Cash, cash equivalents and marketable securities of $753.8M as of Sept 30, 2024, with runway into 2028.","Net loss for Q3 2024 was $49.0M, compared to $20.8M in Q3 2023.","APG777 Phase 2 Part A data expected in 2H 2025; interim Phase 1 data for APG808 in 4Q 2024.","APG333 development candidate nominated; Phase 1 planned for late 2024 or early 2025.","Jeff S. Hartness appointed as Chief Commercial Officer in September 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124542","json":"https://secwatch.observer/filing/0000950170-24-124542.json","markdown":"https://secwatch.observer/filing/0000950170-24-124542.md","text":"https://secwatch.observer/filing/0000950170-24-124542.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000095017024124542/0000950170-24-124542-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000095017024124542/apge-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:20:26.272462+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}